@DalsonFigueired Rapaz, curto muito seu conteudo e vc postando vaga e oportunidade, mas as vezes é osso viu kkkkkkkk
Sem fundamento algum essa afirmação
@opressora Eu tenho um e raramente uso, mas todas as férias eu tento me comprometer a jogar, ja comprei varios jogos steam e coloquei pokemon e zelda de switch mas nao tenho animo 🥲🥲
I still have a lot to learn about RL, but it was really fun to learn some of it through a game I remember from years ago 🤣🤣
I put the code, data and full write-up here:
https://t.co/DgWeDPfSkr
I've been working on a reinforcement learning project with 3D Pinball Space Cadet.
I instrumented the original C++ engine, exposed the game state to Python with pybind11, created a Gymnasium environment and trained a PPO agent.
One thing surprised me a lot: making the agent better at hitting the ball did not improve the score.
Action masking improved the hit rate by 20–35x, and trajectory prediction also helped. But the score still mostly depended on how long the ball stayed alive.
@Pedro_Barciela se a coleta for por nome, um post do tipo "cadê essa indignação toda pro Dark Horse?" entra na amostra sem falar do caso, e sai contado como não-crítico, só que é justamente esse post que é o seu achado, fica difícil separar o que o dado mostrou do que a query trouxe
@Pedro_Barciela Interessante leitura do mecanismo, Pedro, só fiquei curioso com o recorte: qual o corpus e a janela dessas ocorrências? Pergunto porque "48% críticas ao Lulinha" muda bastante de sentido dependendo se o denominador é menção ao caso ou menção ao nome dele.
This is freaking huge: For the first time, a AI-assisted personalized mRNA cancer treatment has succeeded in a Phase 3 trial.
Moderna and Merck sequence each patient’s tumor and compare it with their healthy DNA. AI then helps identify which of the tumor’s mutations are most likely to trigger an immune response.
From those targets, Moderna produces an individual mRNA treatment encoding up to 34 neoantigens, The earlier Phase 2 trial followed patients with surgically removed high-risk melanoma for five years:
- 68.8% remained cancer-free, compared with 49.1% on Keytruda alone
- 49% lower risk of recurrence or death
- 59% lower risk of distant metastasis or death
Now the much larger Phase 3 trial involving 1,137 patients has also succeeded.
Absolutely incredible. Dario was right: cancer will be cured in just a few years!